Home Cart Sign in  
Chemical Structure| 1229705-06-9 Chemical Structure| 1229705-06-9

Structure of Idasanutlin
CAS No.: 1229705-06-9

Chemical Structure| 1229705-06-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Idasanutlin (RG7388) is a potent and selective MDM2 antagonist that inhibits p53-MDM2 binding with an IC50 of 6 nM.

Synonyms: RG7388; Ro 5503781

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Idasanutlin

CAS No. :1229705-06-9
Formula : C31H29Cl2F2N3O4
M.W : 616.48
SMILES Code : O=C(O)C1=CC(OC)=C(NC([C@H]2[C@H](C3=C(F)C(Cl)=CC=C3)[C@](C4=CC=C(Cl)C=C4F)(C#N)[C@H](CC(C)(C)C)N2)=O)C=C1
Synonyms :
RG7388; Ro 5503781
MDL No. :MFCD26142931
InChI Key :TVTXCJFHQKSQQM-LJQIRTBHSA-N
Pubchem ID :53358942

Safety of Idasanutlin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03287245 Polycythemia Vera PHASE2 TERMINATED 2020-03-03 Mayo Clinic - Arizona, Phoenix... More >>, Arizona, 85054, United States|University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, 66205, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Cleveland Clinic Cancer Center, Independence, Ohio, 44131, United States|University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, 78229, United States|Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, 3002, Australia|Princess Margaret Cancer Center, Toronto, Ontario, M5G 1Z5, Canada|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, 24127, Italy|Ospedale Di Circolo E Fondazione Macchi; Ematologia, Varese, Lombardia, 21100, Italy|Az. Ospedaliero-Universitaria Careggi; CRIMM, Firenze, Toscana, 50134, Italy Less <<
NCT03362723 Solid Tumors PHASE1 COMPLETED 2019-06-11 University of Colorado, Aurora... More >>, Colorado, 80045-2517, United States|Yale Cancer Center; Medical Oncology, New Haven, Connecticut, 06520, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, 63110, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, 89169, United States|University of Oklahoma Health Sciences Center; Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|Mary Crowley Medical Research Center, Dallas, Texas, 75230, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Princess Margaret Cancer Center, Toronto, Ontario, M5G 1Z5, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, H3T 1E2, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.62mL

0.32mL

0.16mL

8.11mL

1.62mL

0.81mL

16.22mL

3.24mL

1.62mL

 

Historical Records

Categories